文献速递肝病消化内镜

TIPS减压门静脉高压可逆转肠屏障功能障碍与肝硬化相关免疫功能障碍标志物

Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction.
PubMed 文献 · Gut · 2026-07-30

这项前瞻性队列研究纳入75例接受TIPS的患者和15例代偿期肝硬化对照,检测肠屏障功能障碍、细菌易位、全身炎症和单核细胞活化标志物。结果显示失代偿期患者上述标志物升高,TIPS后显著下降;TIPS还逆转了单核细胞的抗炎表型,且免疫改善仅见于腹水消退者并与细菌感染减少相关。结论认为门静脉高压是CAID的核心驱动因素。

要点

  • 门静脉高压是失代偿期肝硬化相关免疫功能障碍的核心上游驱动因素。
  • TIPS降低门静脉压力后肠屏障功能障碍、细菌易位和炎症标志物显著下降。
  • 免疫改善仅见于腹水消退患者,并与细菌感染减少相关。

核心结论

  • 门静脉高压是失代偿期肝硬化CAID的核心驱动因素,TIPS减压可恢复肠屏障完整性、减轻炎症并重建免疫稳态。

研究设计与样本

  • 前瞻性队列研究纳入接受TIPS的患者75例和代偿期肝硬化对照15例,纵向检测血浆标志物并进行体外单核细胞实验和RNA测序。
  • 免疫学发现与临床结局相关,并在一个外部前瞻性队列和1180例患者的回顾性多中心队列中验证。

主要发现

  • 失代偿期肝硬化患者肠屏障功能障碍、细菌易位、全身炎症和单核细胞活化标志物较代偿期对照升高。
  • 上述标志物在TIPS后显著下降。
  • 失代偿期患者血清在体外诱导单核细胞抗炎标志物MERTK和CD163并抑制IL-6分泌,TIPS后患者血清无此效应。
  • 转录组分析发现失代偿期肝硬化单核细胞抗炎特征,TIPS后消退。
  • CAID改善仅见于腹水消退患者,并与细菌感染减少相关。

临床怎么用

  • TIPS不仅是降低门静脉压力的手段,还可能通过逆转CAID改善失代偿期肝硬化患者的免疫功能和感染相关结局。
  • 腹水消退可作为TIPS后免疫改善的临床观察指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Decompensated cirrhosis is associated with cirrhosis-associated immune dysfunction (CAID), predisposing patients to bacterial infections and poor outcomes. The mechanisms driving CAID remain incompletely understood. OBJECTIVE: To examine whether portal hypertension (PH) is a key upstream driver of CAID and whether its reduction by transjugular intrahepatic portosystemic shunt (TIPS) reverses immune dysfunction. DESIGN: In a prospective cohort study, patients undergoing TIPS (n=75) and controls with compensated cirrhosis (n=15) were included. Plasma markers of gut barrier dysfunction, bacterial translocation, systemic inflammation and monocyte activation were measured in controls and longitudinally before and after TIPS. The effects of patient sera from different stages of cirrhosis on healthy donor-derived monocytes were assessed in vitro. Bulk RNA sequencing was performed on patient monocytes. Immunological findings were correlated with clinical outcomes, which were also validated in an external prospective cohort and a retrospective multicentre cohort of 1180 patients. RESULTS: Patients with decompensated cirrhosis showed elevated markers of gut barrier dysfunction, bacterial translocation, systemic inflammation and monocyte activation compared with compensated controls. These markers significantly decreased after TIPS. Sera from decompensated patients, but not from post-TIPS patients, induced anti-inflammatory markers (MER Tyrosine Kinase (MERTK), CD163) and suppressed interleukin 6 secretion in monocytes in vitro. Transcriptomic analysis identified an anti-inflammatory monocyte signature in decompensated cirrhosis that resolved after TIPS. CAID improvement occurred only in patients with ascites resolution and was associated with fewer bacterial infections. CONCLUSION: PH is a central driver of CAID in decompensated cirrhosis. Its reduction by TIPS restores gut barrier integrity, reduces inflammation and re-establishes immune homeostasis.

来源:Gut,查看原文。版权归原作者所有。

引用

  1. Piecha F, Al Jawazneh A, Buescher G, et al. Decompression of portal hypertension by transjugular intrahepatic portosystemic shunt reverses markers of gut barrier dysfunction and cirrhosis-associated immune dysfunction. Gut. 2026. PMID: 42532671. doi:10.1136/gutjnl-2026-338318

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。